Human ARG1/OTC Stable Cell Line - HepG2

Acute liver failure (ALF) is a life-threatening condition where the liver loses its ability to detoxify harmful substances, such as bilirubin and ammonia. One approach to treat ALF is through the use of bioartificial livers (BAL), which can temporarily take over the liver's detoxification functions, giving patients a chance to recover. In this study, the researchers developed a genetically engineered version of the HepG2 cell line, called SynHeps-II, by overexpressing multiple genes involved in detoxification, including ARG1, OTC, and CPS1. This new cell line demonstrated significant improvements in detoxifying bilirubin and ammonia, both in vitro and in vivo, and also helped reduce inflammation and liver damage in animal models of ALF.

Figure 1. The researchers generated the SynHeps-I cell line by overexpressing UGT1A1 and OATP1B1 in HepG2 cells to detoxify bilirubin. They then created SynHeps-II by adding CPS1, OTC, and ARG1 to SynHeps-I cells, enabling both bilirubin and ammonia detoxification. Western blot analysis confirmed the successful expression of these genes in both cell lines. (Wang K, et al., 2024)

Our Human ARG1/OTC Stable Cell Line - HepG2 is an ideal model for studying liver detoxification mechanisms, including the metabolism of bilirubin and ammonia. This cell line can be used in similar research, providing a valuable tool for preclinical studies on ALF and liver-related diseases.